300238.SZ
冠昊生物
SZSE · Healthcare · C 制造业 · CN
CNY 11.44
−4.27%Year over year
Reported trailing growth
- Revenue
- +1.5%
- EBITDA
- —
- EBIT
- -8.9%
- EPS
- -29.7%
- Free cash flow
- +239.5%
- Operating cash flow
- -20.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +0.9%
- EBITDA
- -7.8%
- EBIT
- -5.3%
- Net income
- -11.4%
- EPS
- -13.4%
- Free cash flow
- +3.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026